Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570938 | 0.85 | AR (0.58) | KDM1AIDO1TDO2AR | |
| SCHEMBL30895187 | 0.82 | CYP11B1 (0.51) | KDM1AIDO1TDO2AR | |
| SCHEMBL17941593 | 0.81 | AR (0.57) | AR | |
| SCHEMBL15976200 | 0.81 | CYP11B1 (0.50) | KDM1AIDO1TDO2AR | |
| SCHEMBL142269 | 0.81 | CYP11B1 (0.50) | KDM1AIDO1TDO2AR | |
| SCHEMBL1704676 | 0.80 | MEN1 (0.43) | KDM1AIDO1TDO2 | |
| SCHEMBL5220716 | 0.80 | DPP4 (0.46) | KDM1A | |
| SCHEMBL4635204 | 0.79 | DPP4 (0.47) | KDM1AIDO1TDO2AR | |
| SCHEMBL1237566 | 0.78 | KDM4E (0.63) | IDO1TDO2 | |
| SCHEMBL2944271 | 0.78 | DRD2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1399433-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002553-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | KDM1A 885/4885IDO1 271/4885TDO2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.